Kim et al. BMC Cancer 2012, 12:147 http://www.biomedcentral.com/1471-2407/12/147 42. Kim JS, Lee JH, Jeong WW, Choi DH, Cha HJ, Kim DH, Kwon JK, Park SE, Park JH, Cho HR, et al: Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells. Int J Cancer 2008, 122:672-680. 43. Mansat-de Mas V, Bezombes C, Quillet-Mary A, Bettaieb A, D’orgeix AD, Laurent G, Jaffrezou JP: Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol 1999, 56:867-874. 44. Tsai-Turton M, Luong BT, Tan Y, Luderer U: Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci 2007, 98:216-230. 45. Brown DP, Chin-Sinex H, Nie B, Mendonca MS, Wang M: Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol 2009, 63:723-730. 46. Kang YH, Lee SJ: The role of p38 MAPK and JNK in Arsenic trioxide- induced mitochondrial cell death in human cervical cancer cells. J Cell Physiol 2008, 217:23-33. 47. Osone S, Hosoi H, Kuwahara Y, Matsumoto Y, Iehara T, Sugimoto T: Fenretinide induces sustained-activation of JNK/p38 MAPK and apoptosis in a reactive oxygen species-dependent manner in neuroblastoma cells. Int J Cancer 2004, 112:219-224. 48. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003, 278:19245-19256. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/12/147/prepub doi:10.1186/1471-2407-12-147 Cite this article as: Kim et al.: Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C. BMC Cancer 2012 12:147. Page 10 of 10 Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit